Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Evaluating Conflicts of Interest in Academic Research On Erythropoietin Receptors in the Cancer Setting

Charles Bennett, MD, PhD, MPP, Eleasa vanSlooten, Matthew Bialkowski, Alyssa Trenery, Ashlyn Byrne, Alanna Murday, BS, Paul Yarnold, Zaina Parvez Qureshi, PhD, MPH, A. Oliver Sartor, MD

Blood (2012) 120 (21): 4695.

https://doi.org/10.1182/blood.V120.21.4695.4695

Published: 2012

Journal Articles

Evaluation of Conflicts of Interest in Basic Science Studies Evaluating Erythropoietin and Erythropoietin Effects of Solid Cancer Cell Lines

Sara E Barnato, MD, Simone N Boyle, BA, Adam Kuykendal, MD, Stephen Y Lai, MD, PhD, Robin L Wagner, Carolyn E Goldstein, Athena T Samaras, BA, Dennis P West, PhD, Jacob Tallman, Michael Henke, MD, A. Oliver Sartor, MD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 672.

https://doi.org/10.1182/blood.V112.11.672.672

Published: 2008

Journal Articles

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Elizabeth A Richey, BA, Veena Shankaran, MD, Steven Hirschfeld, MD, PhD, Steven M Trifilio, RPh, June McKoy, MD, MPH, Kenneth R Carson, MD, Beatrice J Edwards, MD, FACP, Thanh Ha Luu, BA, Narissa Nonzee, BS, A. Oliver Sartor, MD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 2402.

https://doi.org/10.1182/blood.V112.11.2402.2402

Published: 2008

Journal Articles

Erythropoiesis Stimulating Agent (ESA) Use for Anemic Cancer and Chronic Kidney Disease (CKD) Patients in 2008: Advocacy for Conservative Use

Charles L. Bennett, MD, PhD, MPP, Benjamin Kim, MD, Athena T Samaras, BA, Allen R Nissenson, MD, FACP, A. Oliver Sartor, MD, D. Mark Courtney, MD, Robert I. Liem, MD, Dennis P West, PhD, Simone N Boyle, BA, Robin L Wagner, Carolyn E Goldstein, Steven M Trifilio, RPh, David M Spiegel, MD, FACP, Stephen Y Lai, MD, PhD

Blood (2008) 112 (11): 4680.

https://doi.org/10.1182/blood.V112.11.4680.4680

Published: 2008

Journal Articles

Evaluating Mortality with Erythropoietin Stimulating Agents (ESAs) in the Oncology Setting: The Importance of Selecting Trials That Include Survival or Loco-Regional Tumor Control as a Primary Endpoint

Athena T Samaras, BA, Sara E Barnato, MD, Benjamin Kim, MD, Stephen Y Lai, MD, PhD, A. Oliver Sartor, MD, June McKoy, MD, JD, MPH, Brian C Sauer, PhD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 4681.

https://doi.org/10.1182/blood.V112.11.4681.4681

Published: 2008

NARROW

Evaluating Conflicts of Interest in Academic Research On Erythropoietin Receptors in the Cancer Setting

Evaluation of Conflicts of Interest in Basic Science Studies Evaluating Erythropoietin and Erythropoietin Effects of Solid Cancer Cell Lines

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Erythropoiesis Stimulating Agent (ESA) Use for Anemic Cancer and Chronic Kidney Disease (CKD) Patients in 2008: Advocacy for Conservative Use

Evaluating Mortality with Erythropoietin Stimulating Agents (ESAs) in the Oncology Setting: The Importance of Selecting Trials That Include Survival or Loco-Regional Tumor Control as a Primary Endpoint

Email alerts

ASH Publications

American Society of Hematology

Evaluating Conflicts of Interest in Academic Research On Erythropoietin Receptors in the Cancer Setting

Evaluation of Conflicts of Interest in Basic Science Studies Evaluating Erythropoietin and Erythropoietin Effects of Solid Cancer Cell Lines

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Erythropoiesis Stimulating Agent (ESA) Use for Anemic Cancer and Chronic Kidney Disease (CKD) Patients in 2008: Advocacy for Conservative Use

Evaluating Mortality with Erythropoietin Stimulating Agents (ESAs) in the Oncology Setting: The Importance of Selecting Trials That Include Survival or Loco-Regional Tumor Control as a Primary Endpoint

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only